EDWARDS LIFESCIENCES CORP (EW) Stock Fundamental Analysis

NYSE:EW • US28176E1082

78.45 USD
+2.58 (+3.4%)
At close: Feb 17, 2026
78.45 USD
0 (0%)
After Hours: 2/17/2026, 8:12:17 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

EW gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. EW has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. EW is not valued too expensively and it also shows a decent growth rate. These ratings could make EW a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year EW was profitable.
  • EW had a positive operating cash flow in the past year.
  • EW had positive earnings in each of the past 5 years.
  • EW had a positive operating cash flow in 4 of the past 5 years.
EW Yearly Net Income VS EBIT VS OCF VS FCFEW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

1.2 Ratios

  • EW's Return On Assets of 10.31% is amongst the best of the industry. EW outperforms 94.59% of its industry peers.
  • EW has a better Return On Equity (13.40%) than 89.19% of its industry peers.
  • With an excellent Return On Invested Capital value of 12.09%, EW belongs to the best of the industry, outperforming 92.97% of the companies in the same industry.
Industry RankSector Rank
ROA 10.31%
ROE 13.4%
ROIC 12.09%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EW Yearly ROA, ROE, ROICEW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • With an excellent Profit Margin value of 23.25%, EW belongs to the best of the industry, outperforming 95.14% of the companies in the same industry.
  • EW's Profit Margin has been stable in the last couple of years.
  • EW's Operating Margin of 27.73% is amongst the best of the industry. EW outperforms 96.22% of its industry peers.
  • In the last couple of years the Operating Margin of EW has declined.
  • EW's Gross Margin of 78.19% is amongst the best of the industry. EW outperforms 90.81% of its industry peers.
  • In the last couple of years the Gross Margin of EW has remained more or less at the same level.
Industry RankSector Rank
OM 27.73%
PM (TTM) 23.25%
GM 78.19%
OM growth 3Y-8.34%
OM growth 5Y-1.77%
PM growth 3Y-19.64%
PM growth 5Y-1.18%
GM growth 3Y-2.35%
GM growth 5Y0.69%
EW Yearly Profit, Operating, Gross MarginsEW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • EW has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • There is no outstanding debt for EW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EW Yearly Shares OutstandingEW Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
EW Yearly Total Debt VS Total AssetsEW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • EW has an Altman-Z score of 11.68. This indicates that EW is financially healthy and has little risk of bankruptcy at the moment.
  • EW's Altman-Z score of 11.68 is amongst the best of the industry. EW outperforms 91.35% of its industry peers.
  • The Debt to FCF ratio of EW is 0.75, which is an excellent value as it means it would take EW, only 0.75 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.75, EW belongs to the top of the industry, outperforming 90.81% of the companies in the same industry.
  • EW has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • EW's Debt to Equity ratio of 0.06 is fine compared to the rest of the industry. EW outperforms 67.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.75
Altman-Z 11.68
ROIC/WACC1.21
WACC9.96%
EW Yearly LT Debt VS Equity VS FCFEW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

  • EW has a Current Ratio of 4.00. This indicates that EW is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 4.00, EW is doing good in the industry, outperforming 68.11% of the companies in the same industry.
  • A Quick Ratio of 3.29 indicates that EW has no problem at all paying its short term obligations.
  • EW has a Quick ratio of 3.29. This is in the better half of the industry: EW outperforms 68.11% of its industry peers.
Industry RankSector Rank
Current Ratio 4
Quick Ratio 3.29
EW Yearly Current Assets VS Current LiabilitesEW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • EW shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.29%.
  • Measured over the past 5 years, EW shows a small growth in Earnings Per Share. The EPS has been growing by 6.67% on average per year.
  • The Revenue has grown by 10.86% in the past year. This is quite good.
  • EW shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.70% yearly.
EPS 1Y (TTM)-2.29%
EPS 3Y1.06%
EPS 5Y6.67%
EPS Q2Q%-1.69%
Revenue 1Y (TTM)10.86%
Revenue growth 3Y10.77%
Revenue growth 5Y6.7%
Sales Q2Q%13.26%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.79% on average over the next years. This is quite good.
  • EW is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.72% yearly.
EPS Next Y16.14%
EPS Next 2Y13.34%
EPS Next 3Y13.01%
EPS Next 5Y12.79%
Revenue Next Year10.47%
Revenue Next 2Y10.14%
Revenue Next 3Y10.12%
Revenue Next 5Y9.72%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EW Yearly Revenue VS EstimatesEW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B 8B
EW Yearly EPS VS EstimatesEW Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 30.64, EW can be considered very expensive at the moment.
  • 74.05% of the companies in the same industry are more expensive than EW, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.16. EW is around the same levels.
  • With a Price/Forward Earnings ratio of 26.39, EW can be considered very expensive at the moment.
  • EW's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. EW is cheaper than 74.05% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of EW to the average of the S&P500 Index (28.10), we can say EW is valued inline with the index average.
Industry RankSector Rank
PE 30.64
Fwd PE 26.39
EW Price Earnings VS Forward Price EarningsEW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, EW is valued a bit cheaper than the industry average as 73.51% of the companies are valued more expensively.
  • EW's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. EW is cheaper than 71.89% of the companies in the same industry.
Industry RankSector Rank
P/FCF 56.93
EV/EBITDA 23
EW Per share dataEW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates EW does not grow enough to justify the current Price/Earnings ratio.
  • EW has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as EW's earnings are expected to grow with 13.01% in the coming years.
PEG (NY)1.9
PEG (5Y)4.59
EPS Next 2Y13.34%
EPS Next 3Y13.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for EW!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EDWARDS LIFESCIENCES CORP

NYSE:EW (2/17/2026, 8:12:17 PM)

After market: 78.45 0 (0%)

78.45

+2.58 (+3.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)04-21
Inst Owners89.94%
Inst Owner Change-0.52%
Ins Owners0.11%
Ins Owner Change-1%
Market Cap45.52B
Revenue(TTM)6.07B
Net Income(TTM)1.37B
Analysts79.53
Price Target98.01 (24.93%)
Short Float %1.41%
Short Ratio2.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.01%
Min EPS beat(2)4.4%
Max EPS beat(2)9.63%
EPS beat(4)4
Avg EPS beat(4)5.38%
Min EPS beat(4)3.4%
Max EPS beat(4)9.63%
EPS beat(8)5
Avg EPS beat(8)2.27%
EPS beat(12)6
Avg EPS beat(12)1.21%
EPS beat(16)7
Avg EPS beat(16)-0.18%
Revenue beat(2)1
Avg Revenue beat(2)0.37%
Min Revenue beat(2)-0.12%
Max Revenue beat(2)0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.56%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)0.85%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)2
Avg Revenue beat(12)-2.12%
Revenue beat(16)2
Avg Revenue beat(16)-2.48%
PT rev (1m)0.92%
PT rev (3m)9.17%
EPS NQ rev (1m)-0.25%
EPS NQ rev (3m)-0.06%
EPS NY rev (1m)0%
EPS NY rev (3m)0.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.38%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)0.29%
Valuation
Industry RankSector Rank
PE 30.64
Fwd PE 26.39
P/S 7.74
P/FCF 56.93
P/OCF 44.77
P/B 4.46
P/tB 6.23
EV/EBITDA 23
EPS(TTM)2.56
EY3.26%
EPS(NY)2.97
Fwd EY3.79%
FCF(TTM)1.38
FCFY1.76%
OCF(TTM)1.75
OCFY2.23%
SpS10.14
BVpS17.59
TBVpS12.59
PEG (NY)1.9
PEG (5Y)4.59
Graham Number31.83
Profitability
Industry RankSector Rank
ROA 10.31%
ROE 13.4%
ROCE 13.97%
ROIC 12.09%
ROICexc 18.01%
ROICexgc 28.58%
OM 27.73%
PM (TTM) 23.25%
GM 78.19%
FCFM 13.59%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-8.34%
OM growth 5Y-1.77%
PM growth 3Y-19.64%
PM growth 5Y-1.18%
GM growth 3Y-2.35%
GM growth 5Y0.69%
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.75
Debt/EBITDA 0.33
Cap/Depr 138.79%
Cap/Sales 3.69%
Interest Coverage 250
Cash Conversion 56.86%
Profit Quality 58.45%
Current Ratio 4
Quick Ratio 3.29
Altman-Z 11.68
F-Score5
WACC9.96%
ROIC/WACC1.21
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.29%
EPS 3Y1.06%
EPS 5Y6.67%
EPS Q2Q%-1.69%
EPS Next Y16.14%
EPS Next 2Y13.34%
EPS Next 3Y13.01%
EPS Next 5Y12.79%
Revenue 1Y (TTM)10.86%
Revenue growth 3Y10.77%
Revenue growth 5Y6.7%
Sales Q2Q%13.26%
Revenue Next Year10.47%
Revenue Next 2Y10.14%
Revenue Next 3Y10.12%
Revenue Next 5Y9.72%
EBIT growth 1Y4.68%
EBIT growth 3Y1.54%
EBIT growth 5Y4.82%
EBIT Next Year24.3%
EBIT Next 3Y14.62%
EBIT Next 5Y14.72%
FCF growth 1Y67.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.09%
OCF growth 3YN/A
OCF growth 5YN/A

EDWARDS LIFESCIENCES CORP / EW FAQ

What is the fundamental rating for EW stock?

ChartMill assigns a fundamental rating of 6 / 10 to EW.


What is the valuation status for EW stock?

ChartMill assigns a valuation rating of 4 / 10 to EDWARDS LIFESCIENCES CORP (EW). This can be considered as Fairly Valued.


How profitable is EDWARDS LIFESCIENCES CORP (EW) stock?

EDWARDS LIFESCIENCES CORP (EW) has a profitability rating of 7 / 10.


What is the earnings growth outlook for EDWARDS LIFESCIENCES CORP?

The Earnings per Share (EPS) of EDWARDS LIFESCIENCES CORP (EW) is expected to grow by 16.14% in the next year.